Imanext Ltd is a specialized service provider (Contract Research Organisation, CRO) for pharmaceutical and biotechnology industry.
Drug developers will reduce expenses, and get products faster into market by using imaging services of Imanext. Imanext operates in the field of functional imaging, and has the possibility to utilize state-of-art non-clinical and clinical molecular imaging techniques through its global partnership network.

Imanext has established an extensive network of imaging sites and required cGMP manufacturers for molecular imaging. The current list of sites consists of 28 different countries in Europe, America, Asia, Africa, and Australia. Imanext has contracts with the sites making it possible to conduct single-site or multi-center trials.

"Imanext is looking forward to strengthen the network of the imaging sites. The goal is to bring our clients new possibilities for state-of-art non-clinical, and clinical imaging services. The network allows also an efficient use of their R&D budgets to conduct specialized trials", says Kim Bergström, CEO of Imanext Ltd.

Microdosing enables better selections earlier in the drug development process. Microdosing is a new concept which may facilitate drug development process, and it is defined as the use of less 1/100th of the therapeutic dose of an investigated new drug. By labeling the drug molecule, microdosing studies may be performed either by investigating plasma/tissue samples with accelerator mass spectrometry (AMS) [in some cases also using LC-MS-MS systems] or by in vivo radionuclide imaging methods (PET and SPECT).